Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
The ADSs are being offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.
- The ADSs are being offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.
- The Global Offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.
- In particular, no public offering of the ADSs will be made in the European Union or any of its member states.
- These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management.